Compare Stocks → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CMLTNASDAQ:IMNMNASDAQ:SNSENASDAQ:TFFP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMLTCM Life Sciences III$8.69$9.37$8.29▼$11.10$180.10MN/A284,659 shs563,420 shsIMNMImmunome$14.27-2.7%$22.56$4.44▼$30.96$851.78M1.66725,235 shs555,442 shsSNSESensei Biotherapeutics$0.99-1.0%$0.96$0.51▼$1.72$24.86M0.1764,946 shs54,562 shsTFFPTFF Pharmaceuticals$3.01+1.3%$6.10$2.51▼$21.25$7.59M1.2928,365 shs12,712 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMLTCM Life Sciences III0.00%0.00%0.00%0.00%0.00%IMNMImmunome-4.06%-20.33%-39.72%-4.31%+176.60%SNSESensei Biotherapeutics+7.18%+0.97%-14.73%+30.91%-36.85%TFFPTFF Pharmaceuticals+17.25%-8.61%-60.66%-42.92%-79.93%The system that called 2023’s top 7 stocks is at it again… (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMLTCM Life Sciences IIIN/AN/AN/AN/AN/AN/AN/AN/AIMNMImmunome1.4808 of 5 stars3.50.00.00.02.61.70.0SNSESensei Biotherapeutics3.9697 of 5 stars3.53.00.04.80.01.71.3TFFPTFF Pharmaceuticals1.1528 of 5 stars3.53.00.00.00.60.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMLTCM Life Sciences IIIN/AN/AN/AN/AIMNMImmunome3.00Buy$32.67128.92% UpsideSNSESensei Biotherapeutics3.00Buy$4.00303.35% UpsideTFFPTFF Pharmaceuticals3.00Buy$72.002,292.03% UpsideCurrent Analyst RatingsLatest TFFP, IMNM, SNSE, and CMLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.004/1/2024IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$27.00 ➝ $33.003/28/2024TFFPTFF PharmaceuticalsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$56.00 ➝ $44.001/29/2024IMNMImmunomeLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform1/29/2024IMNMImmunomeSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMLTCM Life Sciences IIIN/AN/AN/AN/AN/AN/AIMNMImmunome$14.02M60.75N/AN/A$2.77 per share5.15SNSESensei BiotherapeuticsN/AN/AN/AN/A$2.60 per shareN/ATFFPTFF Pharmaceuticals$730K10.39N/AN/A$4.04 per share0.75Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMLTCM Life Sciences IIIN/AN/A0.00∞N/AN/AN/AN/AN/AIMNMImmunome-$106.81M-$5.39N/AN/AN/A-761.92%-69.74%-31.40%5/3/2024 (Estimated)SNSESensei Biotherapeutics-$34.10M-$1.22N/AN/AN/AN/A-44.01%-38.58%5/14/2024 (Estimated)TFFPTFF Pharmaceuticals-$21.24M-$12.51N/AN/AN/A-2,897.95%-163.14%-144.77%5/9/2024 (Estimated)Latest TFFP, IMNM, SNSE, and CMLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023IMNMImmunome-$0.28-$0.54-$0.26$3.14$3.40 million$3.83 million3/28/2024Q4 2023TFFPTFF Pharmaceuticals-$2.00-$2.01-$0.01-$2.01$0.20 million$0.11 million2/28/2024Q4 2023SNSESensei Biotherapeutics-$0.32-$0.30+$0.02-$0.30N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMLTCM Life Sciences IIIN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMLTCM Life Sciences IIIN/A1.031.03IMNMImmunomeN/A6.636.63SNSESensei Biotherapeutics0.0111.9211.92TFFPTFF PharmaceuticalsN/A3.123.12OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMLTCM Life Sciences III88.48%IMNMImmunome44.58%SNSESensei Biotherapeutics10.50%TFFPTFF Pharmaceuticals15.25%Insider OwnershipCompanyInsider OwnershipCMLTCM Life Sciences IIIN/AIMNMImmunome20.00%SNSESensei Biotherapeutics25.50%TFFPTFF Pharmaceuticals5.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCMLTCM Life Sciences IIIN/A20.73 millionN/ANot OptionableIMNMImmunome5559.69 million47.76 millionOptionableSNSESensei Biotherapeutics2825.07 million18.68 millionNot OptionableTFFPTFF Pharmaceuticals192.52 million2.38 millionOptionableTFFP, IMNM, SNSE, and CMLT HeadlinesSourceHeadlineTFF Pharmaceuticals (TFFP) Price Target Decreased by 28.99% to 24.99msn.com - April 17 at 11:27 PMTFF Pharmaceuticals Reports Addl. Positive Phase 2 Data For Tacrolimus Inhalation Powdermarkets.businessinsider.com - April 15 at 9:43 AMTFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessionsglobenewswire.com - April 15 at 7:00 AMTFF Pharmaceuticals Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - April 1 at 10:13 AMTFF Pharmaceuticals reports positive phase 2 trial resultsinvesting.com - March 29 at 11:52 PMTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Resultsfinanznachrichten.de - March 29 at 8:50 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 28 at 11:31 PMTFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 28 at 4:05 PMTFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programsglobenewswire.com - March 27 at 4:01 PMTFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meetingglobenewswire.com - March 25 at 9:01 AMTFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesglobenewswire.com - March 22 at 3:11 PMTFF Pharmaceuticals, Inc. (TFFP)finance.yahoo.com - March 21 at 9:12 PMTFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesglobenewswire.com - March 20 at 12:00 PMTFF Pharmaceuticals Announces Update on Clinical Programsglobenewswire.com - March 20 at 9:03 AMTFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024globenewswire.com - March 14 at 4:47 PMTff Pharmaceuticals Inc (TFFP)uk.investing.com - March 12 at 6:49 PMTFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conferencefinance.yahoo.com - January 24 at 10:43 AMTFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meetingfinance.yahoo.com - January 9 at 10:39 AMTFF Pharmaceuticals Inc Ordinary Sharesmorningstar.com - January 5 at 1:08 PMPositive Phase II Results Bolster Buy Rating for TFF Pharmaceuticals with Raised Price Targetmarkets.businessinsider.com - December 21 at 8:22 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q3 2023investorplace.com - December 20 at 11:12 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2023investorplace.com - December 20 at 11:12 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Misses Revenue for Q1 2023investorplace.com - December 20 at 11:12 AMTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TACfinanznachrichten.de - December 19 at 8:56 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCM Life Sciences IIINASDAQ:CMLTCM Life Sciences III Inc. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.ImmunomeNASDAQ:IMNMImmunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Sensei BiotherapeuticsNASDAQ:SNSESensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.TFF PharmaceuticalsNASDAQ:TFFPTFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.